BlackLine Appoints Greg Hughes to Board of Directors, Expanding Enterprise Software and Strategic Growth Expertise
Hughes most recently served as CEO of Veritas, a global leader in data protection and other mission-critical software. Under his leadership, Veritas re-ignited ARR growth, successfully transitioned to a new subscription pricing model, and created and scaled a cloud business. The transformation of Veritas culminated in a merger of the data protection business with Cohesity, an AI-powered data security and management company. Hughes continues to serve on the board of the merged entity.
In addition to his executive roles, Hughes brings significant public board experience, having served on the board of LogMeIn, a publicly traded collaboration software company, from 2011 to 2017.
Hughes' appointment follows the addition of Sam Balaji, former CEO of Deloitte Consulting, to BlackLine's board in June 2025. Together, Hughes and Balaji bring decades of executive leadership across enterprise software, consulting, cybersecurity, and digital transformation—adding to an already experienced and engaged board that continues to play a vital role in guiding BlackLine's growth and innovation strategy.
"We are thrilled to welcome Greg to BlackLine's Board of Directors," said Owen Ryan, Co-CEO and Chairman of the Board of BlackLine. "With Greg and Sam joining an already strong and strategic board, we are deepening our bench of expertise in enterprise technology, global operations, and transformation at scale. The collective leadership and experience of our board is a powerful asset as we continue executing our strategy and delivering long-term value to our customers and shareholders."
"Greg's track record of scaling companies and leading through inflection points makes him a natural fit for BlackLine," added Therese Tucker, Co-CEO and Founder of BlackLine. "He understands what it takes to build and grow category-defining platforms, and I'm excited to welcome him as we continue to innovate for the Office of the CFO."
"BlackLine has built a differentiated platform with significant opportunities ahead," said Greg Hughes. "I'm honored to join the board and look forward to working with the other board members and leadership team to help advance the company's strategy and support its continued momentum as a category leader in financial operations."
About BlackLine
BlackLine (Nasdaq: BL), the future-ready platform for the Office of the CFO, drives digital finance transformation by empowering organizations with accurate, efficient, and intelligent financial operations.
BlackLine's comprehensive platform addresses mission-critical processes, including record-to-report and invoice-to-cash, enabling unified and accurate data, streamlined and optimized processes, and real-time insight through visibility, automation, and AI. BlackLine's proven, collaborative approach ensures continuous transformation, delivering immediate impact and sustained value. With a proven track record of innovation, industry-leading R&D investment, and world-class security practices, more than 4,400 customers across multiple industries partner with BlackLine to lead their organizations into the future.
For more information, please visit blackline.com.
Media Contact
Samantha Darilek
VP, Communications,
[email protected]
Investor Contact:
Matt Humphries
SVP, Investor Relations,
[email protected]
Safe Harbor
This document contains forward-looking statements. These statements may relate to, but are not limited to, expectations of future operating results or financial performance of BlackLine, Inc. ("BlackLine" or the "Company"), the calculation of certain key financial and operating metrics, capital expenditures, introduction of new solutions or products, expansion into new markets, regulatory compliance, plans for growth and future operations, technological capabilities, and strategic relationships, as well as assumptions relating to the foregoing. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "expect," "plan," anticipate," "believe," "estimate," "predict," "intend," "potential," "would," "continue," "ongoing" or the negative of these terms or other comparable terminology. You should not put undue reliance on any forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved, if at all.
Forward-looking statements are based on information available at the time those statements are made and/or management's good faith beliefs and assumptions as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward looking statements. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this presentation may not occur and actual results could differ materially from those anticipated or implied in the forward-looking statements. These risks and uncertainties are described in greater detail under the heading "Risk Factors" in the filings we make with the Securities and Exchange Commission ("SEC") from time to time, which are available on our website at http://investors.BlackLine.com and on the SEC's website at www.sec.gov. Except as required by law, BlackLine does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.
In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this presentation, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.
In addition to U.S. GAAP financials, this document includes certain non-GAAP financial measures, including non-GAAP revenue, gross profit, gross margin, free cash flow, sales and marketing expense, research and development expense, general and administrative expense, loss from operations and operating margin (loss). These non-GAAP measures are in addition to, not a substitute for or superior to, measures of financial performance prepared in accordance with U.S. GAAP. The non-GAAP financial measures we use may differ from the non-GAAP financial measures used by other companies.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
2 hours ago
- Globe and Mail
Is C3.ai Stock a Buy?
Key Points business has benefited from organizations rushing to adopt AI solutions, such as the U.S. Air Force. The company reached record revenue in its fiscal fourth quarter, and forecasts more sales growth ahead. is not profitable, and a change in CEO is on the horizon. 10 stocks we like better than › Artificial intelligence (AI) stocks have been hot, and many experienced strong growth in 2025 alone. For example, this year, AI luminaries Nvidia and Broadcom saw shares soar more than 30% and 26%, respectively, through July 28. But one lackluster AI stock has been (NYSE: AI). Its shares are down about 25% this year through July 28. Could the price drop signal an opportunity to scoop up shares at a discount? After all, the global AI market is forecast to expand from $244 billion in 2025 to $1 trillion by 2031, providing a tailwind for business. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » The reality is that evaluating whether to purchase its stock requires digging into the company. Let's delve into to help assess if it's a sound investment for the long run. A look at business is an enterprise AI applications business servicing the needs of corporate and government organizations. Its customers include the U.S. Department of Defense, Dow Inc., and ExxonMobil. The company built a network of partnerships to assist in selling its solutions, which includes Microsoft and energy giant Baker Hughes. These alliances resulted in partners closing 73% of the customer agreements signed in 2025 fiscal year, ended April 30. business model translated into record revenue of $108.7 million, a 26% year-over-year increase, in its fiscal fourth quarter. For the full year, sales grew 25% year over year to $389.1 million. The company's offerings have proven popular with customers. In May, the U.S. Air Force expanded its contract with from $100 million to $450 million to supply predictive analytics that proactively identify aircraft maintenance needs. In June, Univation Technologies, a Dow subsidiary, adopted predictive maintenance capabilities to deliver to its petrochemical industry customers. pros and cons The company's customer wins this year suggest more revenue expansion to come. In fact, forecasts fiscal 2026 sales to reach between $447.5 million and $484.5 million, another solid year of growth over fiscal 2025's $389.1 million. Despite rising sales, business isn't profitable. It ended fiscal 2025 with an operating loss of $324.4 million, deepening from a $318.3 million loss in the prior year. Costs increased from adding employees to support its business growth. On top of that, a health issue struck CEO Tom Siebel this year, and the company is now searching for a successor. This is unfortunate news, and it contributed to the decline in share price. The stock price drop is understandable, since a leadership change risks disrupting the company's future success. However, is striving to cut costs and strengthen its finances. Management expects to be free-cash-flow (FCF) positive by next year. It ended fiscal 2025 with negative FCF of $44.4 million, which is an improvement over the previous year's $90.4 million in negative FCF. Its balance sheet shows is well capitalized with total assets of $1 billion, $742.7 million of which represent cash, cash equivalents, and short-term investments. Total liabilities were $187.6 million. Deciding whether to buy stock Although isn't profitable, its strategy to prioritize business expansion over immediate profit follows a typical approach adopted by many companies in the technology sector. As long as year-over-year revenue growth remains strong and it continues to improve its financials, such as reaching positive FCF, operating loss isn't a major concern. The impending departure of its CEO is regrettable, but Siebel intends to continue shepherding the company as executive chairman. This positions for a smooth leadership transition. With plenty of positives in its favor, does this mean now is the time to buy shares? To answer that, here's a look at its stock's price-to-sales (P/S) ratio with a comparison to Microsoft's, given Microsoft sells offerings, and is a prominent AI business in its own right. Data by YCharts. The chart reveals valuation has significantly improved, as evidenced by the substantial drop in its P/S multiple from its late 2024 peak. This multiple is now considerably lower than Microsoft's, further highlighting attractive valuation. This, combined with growing sales, a robust balance sheet, and strengthening free cash flow, makes stock a compelling investment opportunity. Should you invest $1,000 in right now? Before you buy stock in consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* Now, it's worth noting Stock Advisor's total average return is 1,019% — a market-crushing outperformance compared to 178% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. *Stock Advisor returns as of July 29, 2025
Globe and Mail
4 hours ago
- Globe and Mail
3 Unstoppable Stocks to Buy in August
Key Points Investors have multiple reasons to like AbbVie stock. Eli Lilly remains a top stock to buy and hold. Vertex Pharmaceuticals is moving quickly to expand its markets beyond cystic fibrosis. 10 stocks we like better than AbbVie › The "it" factor. Some stocks have it. Other stocks don't. But the ones that do can be virtually unstoppable. Three Motley Fool contributors believe they've found such unstoppable stocks with the "it" factor to buy in August -- and they're all in the healthcare sector. Here's why they picked AbbVie (NYSE: ABBV), Eli Lilly (NYSE: LLY), and Vertex Pharmaceuticals (NASDAQ: VRTX). There are many reasons to buy this stock Prosper Junior Bakiny (AbbVie): It's been a little over two years since AbbVie lost patent exclusivity for its best-selling drug, autoimmune disease medicine Humira. That didn't stop AbbVie, though; it just slowed it down momentarily. The company rebounded nicely and has since returned to top-line growth. AbbVie now owns another one of the top-10 selling therapies in the world, Skyrizi, which targets several immunology conditions. Skyrizi's sales have been growing at an incredibly rapid rate. Together with Rinvoq, AbbVie's immunology lineup has successfully filled the gap left by Humira. That's an important reason to consider the stock: AbbVie's ability to overcome a significant patent cliff speaks volumes about its innovative abilities. Beyond that, AbbVie's lineup is deep. It features older products that continue to make meaningful contributions to its financial results, such as its Botox franchise, and newer products that can help drive top-line growth for a while, like migraine treatment Qulipta. AbbVie's pipeline also looks deep. The company should be able to record consistent clinical and regulatory wins. Lastly, we can't mention AbbVie without pointing out its incredible dividend track record. The company is part of the exclusive group of Dividend Kings, boasting an active streak of 53 consecutive payout increases, which includes the time it spent as a division of its former parent company, Abbott Laboratories. AbbVie's forward yield of 3.5% is much higher than the S&P 500 's average of 1.3%, and its cash payout ratio looks reasonable at 61.8%. In addition to an excellent underlying business, a strong lineup, and a solid pipeline, AbbVie is an outstanding stock for income-seeking investors. Investing in this company could yield superior returns over the long term. Eli Lilly is a top growth stock to own for years David Jagielski (Eli Lilly): A stock that looks unstoppable right now is Eli Lilly. While many investors will focus on its highly successful GLP-1 drugs, Zepbound and Mounjaro, as the main reasons to invest in the business, there's much more behind the company, and why it's a top growth stock. Eli Lilly has a promising Alzheimer's treatment, Kisunla, which regulators approved for use last year. It's still in the early innings of its growth and according to analysts, it could generate up to $5 billion in annual revenue at its peak. Meanwhile, Eli Lilly is still focusing on developing more life-changing treatments for patients. It's planning to invest $4.5 billion into a research and manufacturing facility, which it calls Lilly Medicine Foundry. By utilizing new manufacturing methods to ensure high efficiency, the new center can help the company scale and bring new products to market faster. The company also has vast resources at its disposal, which can help it invest in research and development and potentially acquire promising businesses along the way. In the trailing 12 months, Eli Lilly has generated $11.1 billion in profit on sales totaling $49 billion. The company's terrific margins, strong growth prospects, and commitment to producing new treatments are why this pharmaceutical stock can be among the best investments you can put in your portfolio right now. A big biotech innovator that's targeting new markets Keith Speights (Vertex Pharmaceuticals): To truly be unstoppable, a company can't have competition that could, well, stop it. Vertex Pharmaceuticals has this covered with its cystic fibrosis (CF) franchise. No other drugmaker has approved therapies that treat the underlying cause of CF. The number of companies with experimental CF therapies in late-stage clinical testing that could compete with Vertex totals... zero. Actually, Vertex's biggest rival in treating CF is itself. The company's newest CF therapy, Alyftrek, offers a more convenient once-per-day dosing than its current top-seller, Kaftrio/Trikafta. However, CF isn't the main reason why I like Vertex. My primary interests lie with other indications the biotech innovator is targeting. For example, Vertex won U.S. regulatory approval for Journavx earlier this year. It's the first new class of pain medication in over 20 years. Journavx is safe and effective, with none of the side effects and addictive potential associated with opioids -- because it isn't an opioid. The company's pipeline features promising late-stage programs that could further expand Vertex's market opportunity. Inaxaplin targets APOL1-mediated kidney disease, which affects around 250,000 patients worldwide. Povetacicept holds the potential to treat multiple kidney diseases, with IgA nephropathy first on the list with a patient population of over 1 million. Zimislecel could cure severe type 1 diabetes. At first glance, Vertex might seem to be priced at a premium, with its shares trading at 26.3 times forward earnings. However, the company's growth prospects are so strong that its valuation is attractive. Vertex's price-to-earnings-to-growth (PEG) ratio, based on analysts' five-year earnings growth estimates, is a super-low 0.58. Should you invest $1,000 in AbbVie right now? Before you buy stock in AbbVie, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AbbVie wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $625,254!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,090,257!* Now, it's worth noting Stock Advisor's total average return is 1,036% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 David Jagielski has no position in any of the stocks mentioned. Keith Speights has positions in AbbVie and Vertex Pharmaceuticals. Prosper Junior Bakiny has positions in Eli Lilly and Vertex Pharmaceuticals. The Motley Fool has positions in and recommends AbbVie, Abbott Laboratories, and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.
Globe and Mail
4 hours ago
- Globe and Mail
3 Best AI Stocks to Buy in August
Key Points A European AI infrastructure company is quietly outgrowing established cloud giants with purpose-built technology and strategic positioning. The productivity software leader is successfully monetizing AI integration across its massive user base, while competitors struggle with adoption. The social media giant's AI investments are already paying dividends in advertising revenue even as it pursues ambitious superintelligence goals. 10 stocks we like better than Nebius Group › Artificial intelligence (AI) is one of the most transformative technologies of our time, driving unprecedented advancements in sectors ranging from healthcare and transportation to communications and beyond. For investors, this creates a landmark opportunity to back the companies at the forefront of this revolution. As we head into August, three companies in particular stand out for their strategic positioning and potential for growth in the AI space. The European dark horse with massive ambitions Nebius Group (NASDAQ: NBIS) is emerging as a serious contender in the AI infrastructure race. The Amsterdam-based company, led by former Yandex founder Arkady Volozh, reported staggering 385% year-over-year revenue growth in Q1 2025, reaching $55.3 million, driven primarily by demand for its AI infrastructure services. The stock has surged 92% year to date as investors begin to take notice. What sets Nebius apart is its vertically integrated approach. Rather than retrofitting general-purpose cloud infrastructure for AI workloads, Nebius builds custom hardware and software specifically for intensive AI training and inference. The company expects to reach $750 million to $1 billion in annual recurring revenue (ARR) by the end of 2025. Backed by 94% low-carbon electricity and a Europe-first strategy, Nebius is positioning itself as a credible long-term alternative to the U.S. hyperscalers, making it one of the most compelling buy-and-hold plays in the AI infrastructure space. The productivity powerhouse monetizing AI at scale Microsoft (NASDAQ: MSFT) stands out as the most pragmatic AI play in tech, with shares up roughly 24% year to date. In fiscal year 2025, the company reported that Azure and other cloud services generated more than $75 billion in revenue, marking a 34% year over year increase. Microsoft also posted $76.4 billion in total revenue for its fiscal fourth quarter, beating analyst expectations and pushing shares to new highs. Microsoft's strength lies in its integration strategy. Rather than launching stand-alone AI tools, the company has embedded Copilot across its core productivity suite, contributing to measurable growth across Microsoft 365 and cloud services. Teams Phone adoption surpassed 20 million users, and Copilot-enabled services now reach more than 100 million. With over a billion users across Office and Windows, Microsoft has unmatched distribution for scaling AI tools globally. The company plans to invest $30 billion this quarter alone in AI-enabled infrastructure, reinforcing its leadership in both profitability and long-term platform dominance. What's the bottom line? While others race to catch up, Microsoft is already cashing in, turning its massive installed base into the most profitable AI deployment machine on the planet. The advertising giant reimagining social with superintelligence Meta Platforms (NASDAQ: META) is taking the most aggressive swing at AI integration, with shares climbing 29% year to date after a blowout Q2. Total revenue hit $47.5 billion, up 22% from the prior year, with advertising contributing $46.6 billion and outperforming expectations. CEO Mark Zuckerberg's push to embed "personal superintelligence" across its platforms is beginning to show measurable traction. Advanced AI tools are powering more precise ad delivery and improved monetization, while the company's $14.3 billion stake in Scale AI signals an intent to anchor the next generation of core models. Daily engagement remains strong, with 3.48 billion people using Meta's apps each day as of June 2025, a 6% year-over-year gain. Meta lifted its full-year capital expenditure forecast to between $66 billion and $72 billion, largely to support AI infrastructure and training. But with profit engines running at full speed and unmatched insight into user behavior, Meta is gearing up to dominate the global attention economy. The AI infrastructure build-out is just beginning These three companies represent distinct strategies in the ongoing AI hyperbuild. Nebius offers pure-play infrastructure exposure with a European edge; Microsoft delivers integrated productivity gains with immediate monetization; and Meta combines massive social scale with leading-edge AI development. For long-term investors, holding all three offers a balanced way to capture the full spectrum of AI-driven value creation. Should you invest $1,000 in Nebius Group right now? Before you buy stock in Nebius Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Nebius Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $625,254!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,090,257!* Now, it's worth noting Stock Advisor's total average return is 1,036% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025
